Suzanne Shelley

The SP channel continues to grow, with manufacturers looking for more control over access

Given the accelerating growth of electronic health record (EHR) adoption, pharma marketers are hoping for a new communication channel to open up at the point of care in the physician's office

The healthcare system is coming to grips with the wave of genomic diagnostics that has followed new biological therapy introductions

Oncology combines some of the most life-changing therapeutic events with the most complex commercialization pathways. Rising costs of treatments simply add to the tension

But the global picture is sunny as most of the global market growth benefits the generic makers

Even as diagnosed (and “prediabetes”) cases rise worldwide, healthcare providers struggle with patients to control the course of the disease. New therapies—and new health services—are aiding in the battle

The industry is far from ready when it comes to collecting, aggregating, cleansing and disclosing data about regulated financial transactions with doctors and hospitals

Nearly 200 drugs now carry requirements for a risk management program, as FDA evaluates the initial follow-up reporting from manufacturers

Once reserved for uninsured, many patient-assistance programs have evolved to meet the needs of the under-insured. On the horizon: the potential effects of healthcare reform law

A looming crisis in drug-resistant anti-infectives is not being met with a commensurate industry effort. Governments and industry are trying to cope

As hundreds of candidate drugs receive official “orphan” status, the Orphan Drug Act gets re-examined. Meanwhile, these drugs are driving the growth of specialty pharmacy

Even while cutting the costs of recalls and returns, providers offer new marketing tools to industry

While staff sales forces continue to shrink, the contract sales business is expected to nearly double over the next five years

50 Years of Birth Control: Pharma Continues to Push for More Reproductive-Health Options

Some healthcare providers are pushing for OTC access to birth control. Pharma appears to be on the sideline in the debate

Patient Outcomes Research Moves Drug Development Beyond Clinical Results

FDA’s requirements for risk evaluation and mitigation challenge both new and existing commercialization processes

The current FDA policy toward REMS is being challenged by Allergan

Program seeks to improve the economics of care for low-income families; more sites to come

While nurses move into a more central role in prescribing and administering pharmaceuticals, the nursing professions debate industry influence

Program seeks to improve the economics of care for low-income families; more sites to come

Central nervous system (CNS) medication for society’s oldest and youngest present special challenges

Antipsychotic and antidepressant drugs have risen to the top categories of prescribed medications in a challenging and risky medical and regulatory arena

Mature product franchises and mixed clinical outcomes have not dissuaded pharma companies from expending marketing resources for cardiovascular disease treatment